BACILLUS COMPOSITIONS AND USES THEREOF Cross-Reference to Related Applications [0001] This application claims the benefit of priority to U.S. Provisional Application No. 63/328,607, filed April 7, 2022, the entire contents of which is incorporated herein by reference in its entirety. Technical Field [0002] A unique spore-forming Bacillus species, and more particularly, a Bacillus subtilis strain identified as BS50 is provided. The disclosure also relates to compositions comprising the BS50 strain, methods of making products comprising the same, and methods of using the same. Background [0003] The term “probiotic” is generally used to refer to live microbes that provide health benefits or other positive effects when administered (e.g., by ingestion of a probiotic-containing food or dietary supplement). Probiotics may benefit a host directly, e.g., by excreting compounds that interact with the host’s gastrointestinal (GI) system or by expressing useful enzymes that are absent from or insufficiently expressed by the host. Probiotics may also benefit the host indirectly by interacting with other gut microbes in a manner that has a beneficial effect on the host, e.g., by displacing pathogenic bacteria. The precise nature of these interactions is often poorly understood due to the complexity of the GI system and the gut microbiota. However, the probiotic activity of a microbe can be evaluated based on the detection and measurement of its effects on a host regardless of whether the precise mechanism underlying the effects remains unknown. [0004] In recent years, probiotics have emerged as promising candidates for dietary supplements and therapeutics intended to promote gastrointestinal health, digestive health, immune health, and other physiological benefits. Probiotic microbes have been identified across several genera, including Akkermansia, Anaerobutyricum, Bacillus, Bifidobacterium, Clostridium, Enterococcus, Faecalibacterium, Lacticaseibacillus, Lactiplantibacillus, Lactobacillus, Ligilactobacillus, Limosilactobacillus, Propionibacterium, Saccharomyces, Streptococcus, and Weizmannia. [0005] Traditionally, the inclusion of probiotics suitable for human consumption in foods and beverages has been limited to fermented foods and dairy compositions (e.g., miso, tempeh, kefir, buttermilk, cheese, and yogurt), which provide an environment suitable to allow a sufficient amount of the probiotic bacteria to survive during typical storage conditions (e.g., refrigerated). More recently, dietary supplements (e.g., tablets, sachets, and other delivery vehicles) have been developed which are suitable for at least some probiotics. However, concerns related to survivability, durability, and stability limit the widespread use of many probiotics. In particular, many of the currently known probiotics cannot survive high temperatures for extended periods of time without additional manipulations (e.g., microencapsulation), substantially limiting the types of foods and supplements that may be used as a delivery vehicle for non-spore forming probiotics. Summary of Various Aspects [0006] In a general aspect, the present disclosure relates to a novel, spore-forming Bacillus species, and more particularly, to Bacillus subtilis strain BS50, a sample of which has been deposited under ATCC Accession Number PTA-127287. Bacillus subtilis strain BS50 is capable of surviving extended exposure to high temperatures and stable when stored for prolonged periods (e.g., as a spore). As such, in one aspect, the disclosed bacteria overcomes limitations of prior bacterial species used as probiotics. [0007] In other general aspects, compositions, supplements and other delivery vehicles comprising the BS50 strain are disclosed. In particular aspects, compositions, such as food products, beverage products, and dietary supplements comprising the BS50 strain are provided. [0008] In some aspects, a food product comprising BS50 cells and/or spores is provided. The food product may be probiotic (e.g., comprising BS50 in an amount effective to provide a health benefit or other beneficial effect when administered to a human or animal). In some aspects, the food product is a grain product, bread, cookie, cracker, bar, dairy product, or confection. The BS50 may be present at a concentration of at least 1 x 10 ⁶ , 1 x 10 ⁷ , 1 x 10 ⁸ , 1 x 10 ⁹ , or 2 x 10 ⁹ colony-forming units (CFUs)/gram, or an amount of at least 1 x 10 ⁶ , 1 x 10 ⁷ , 1 x 10 ⁸ , 1 x 10 ⁹ , or 2 x 10 ⁹ CFUs per food product or serving of the food product. The food product may comprise flour, and/or at least one other probiotic, such as a species of Weizmannia genus (formerly Bacillus), and Lactobacillaceae family of the Bacillota phylum (formerly Firmicutes), and species from the Bifidobacterium genus of the Actinomycetota phylum (formerly Actinobacteria). [0009] In other aspects, the disclosure provides beverages (e.g., juice, dairy product, non- dairy milk alternative, legume-based milk alternative, nut-based milk alternative, carbonated water, soda, tea, kombucha, kefir, coffee, sports drink, energy drink, or alcoholic beverage) comprising BS50 at a concentration of at least 1 x 10 ⁶ , 1 x 10 ⁷ , 1 x 10 ⁸ , 1 x 10 ⁹ , or 2 x 10 ⁹ CFUs/gram. The beverage may comprise at least one other probiotic, such as a strain from the genus Lactobacillus or Bifidobacterium. The beverage may also comprise one or more of the following additives: natural sweeteners (e.g., cane sugar, corn syrup, sucrose, maltodextrin, agave syrup or powder, stevia and stevia leaf derivatives, monk fruit powder or extract, etc.), artificial sweeteners (e.g., sucralose, acesulfame potassium, aspartame, etc.), soluble fiber (e.g., pectin, inulin, beta-glucans, fructo-oligosaccharides, galacto-oligosaccharides, xylo- oligosaccharides, arabino-xylooligosaccharides, psyllium, wheat dextrin, polydextrose, carboxymethylcellulose, guar gum and guar gum derivatives, oat powder and other oat derivatives, chickpea powder and other chickpea derivatives, pea powder and other pea derivatives, etc.), insoluble fiber (e.g., cellulose, lignin, wheat bran, etc.), flavoring agents, colorants/dyes, stabilizers, preservatives, oils (e.g., fatty acids, soybean oil, safflower oil, corn oil, peanut oil, coconut oil, medium chain triglycerides, etc.), emulsifiers, vitamins, minerals, proteins, amino acids, and/or peptides. [0010] In other aspects, the disclosure provides dietary supplements (e.g., a powder, tablet, pill, sachet, capsule, or suspension) comprising BS50. The BS50 may be present at a concentration of at least 1 x 10 ⁶ , 1 x 10 ⁷ , 1 x 10 ⁸ , 1 x 10 ⁹ , 2 x 10 ⁹ , or 1 x 10 ¹⁰ CFUs/gram. The dietary supplement may comprise at least one other probiotic, such as a strain from the genus Lactobacillus or Bifidobacterium. In some aspects, the supplement may include spray-dried BS50 spores. The dietary supplement may also comprise one or more of the following additives: natural sweeteners (e.g., cane sugar, corn syrup, sucrose, maltodextrin, agave syrup or powder, stevia and stevia leaf derivatives, monk fruit powder or extract, etc.), artificial sweeteners (e.g., sucralose, acesulfame potassium, aspartame, etc.), soluble fiber (e.g., pectin, inulin, beta-glucans, fructo-oligosaccharides, galacto-oligosaccharides, xylo-oligosaccharides, arabino-xylooligosaccharides, psyllium, wheat dextrin, polydextrose, carboxymethylcellulose, guar gum and guar gum derivatives, oat powder and other oat derivatives, chickpea powder and other chickpea derivatives, pea powder and other pea derivatives, etc.), insoluble fiber (e.g., cellulose, lignin, wheat bran, etc.), flavoring agents, colorants/dyes, stabilizers, preservatives, anti-caking agents, vitamins, minerals, proteins, peptides, and/or amino acids. [0011] In other aspects, the disclosure provides pet food compositions comprising BS50. These compositions may be generally formulated similarly to the disclosed food products and beverages. The pet food may be a dry mixture or a wet mixture. In some aspects, it may comprise one or more fatty acids, free amino acids, or protein, and optionally one or more additional probiotics. [0012] In further aspects, the disclosure provides methods of making and using compositions comprising BS50. For example, methods of using BS50 to provide a health benefit or other beneficial effect to a human or animal are disclosed. In some aspects, the methods are directed to supporting digestive health, supporting gastrointestinal health, and/or reducing gastrointestinal symptoms (e.g., one or more of abdominal bloating, flatulence, burping, stomach rumbling, diarrhea, constipation, loose stool, or firm stool). In some aspects, the methods are directed to supporting immune health and/or supporting healthy blood levels of anti-inflammatory cytokines (e.g., interleukin-10 (IL-10)) and/or decreasing the number of pathogenic bacteria across the intestine. In other aspects, the B. subtilis strain BS50 may be administered in an aerosol, for example by way of a nasal spray, for instance for administration to the respiratory tract. In other aspects, the B. subtilis strain BS50 may be administered topically, for example by way of a lotion, cream, for instance for administration to the skin. [0013] In any of the aspects described herein, the B. subtilis strain BS50 may be in a lyophilized or spray dried form. In other aspects, the B. subtilis strain BS50 may be heat treated, filtered to remove viable cells, or both. [0014] Additional aspects will be readily apparent to one of skill in light of the totality of the disclosure. Brief Description of the Drawings [0015] FIG.1 is a graph illustrating the durability of B. subtilis strain BS50 at 70, 80, 90, and 100 ^C. [0016] FIG. 2 is a graph illustrating the durability of B. subtilis strain BS50 vs. another typical B. subtilis strain at 90 ^C. [0017] FIG.3 is a graph illustrating the survivability of B. subtilis strain BS50 at room temperature. [0018] FIG.4A depicts the survivability of B. subtilis strain BS50 at acidic pH levels over time. FIG.4B depicts the survivability of B. subtilis BS50 at alkaline pH levels. [0019] FIG.5 depicts the survivability of B. subtills strain BS50 in tea steeped at increasing temperatures. [0020] FIG. 6 illustrates the compatibility between B. subtilis strain BS50 and other probiotics. [0021] FIG.7 is a graph illustrating B. subtilis strain BS50 pathogen inhibition activity. Detailed Description of Various Aspects [0022] The present disclosure relates to a unique spore-forming Bacillus species, and more particularly, to a B. subtilis BS50 strain which has been deposited as ATCC Accession Number PTA-127287. Compositions comprising B. subtilis BS50 and methods of making and using the same are also provided. [0023] The microbiota, or ecosystem of microbes and all microbial strains therein, of a typical human gastrointestinal tract is understood to contain approximately 10 ¹⁴ cells, comprising several hundred different bacterial species. Interactions between the gut microbiota and the host’s gastrointestinal, digestive, and immune systems are believed to play a fundamental role in influencing physiological and homeostatic functions of the host. In essence, the gut microbiota may be considered to function as a separate organ. Disruption of the complex interplay between the host’s systems and the gut microbiota can lead to the development of diseases and negative physiological effects. For example, pathogenic bacteria may displace commensal microbes—microbes living in harmony within its host—or explicitly beneficial gut microbes, resulting in inflammation and/or other gastrointestinal diseases, infections, or disorders. Similarly, a host’s gut microbiota may lack a commensal microbe or beneficial microbe, whether due to natural processes or due to exposure to an antibiotic. In each case, an imbalance of beneficial, commensal, and pathogenic microbes exists in the gut microbiota compared to the host’s usual gut microbiota, resulting in disease risk and/or detrimental effects for the host. This microbial imbalance is also referred to as dysbiosis. [0024] In order to restore gut microbiota balance, the host may be administered a probiotic food composition, dietary supplement, or other suitable vehicle comprising the probiotic in a quantity sufficient to support colonization and/or maintenance of beneficial and commensal microbes, or otherwise shift the imbalanced microbiota toward a more usual, healthy microbiota. However, due to survivability issues, current probiotics are limited to a relatively narrow range of foods, beverages, and dietary supplement dosage forms. In particular, probiotics of the Lactobacillaceae family and Bifidobacterium genus may be unsuitable for foods, beverages, and dietary supplements exposed to high temperatures or varying pH conditions. As a result, many types of food matrices (e.g., baked goods, powdered supplements, heat-treated beverages, shelf-stable beverages) and other similar products are not practical for live probiotic formulation. [0025] The B. subtilis BS50 strain disclosed herein addresses these and other shortcomings. For example, probiotic compositions having excellent survivability across a wide range of temperatures and pH levels are provided. In particular, the BS50 strain is a particularly well- suited probiotic for foods, such as baked goods, and other food products or dietary supplements exposed to high temperatures during production or storage. The BS50 strain is also useful as, among other things, a cleaning product or other products used for reduction of deleterious microbes where temperature, pH and/or chemicals may present a concern for other less hardy microbes. [0026] The BS50 strain is a gram-positive, spore forming, rod-shaped facultative anaerobe. Initial characterization assays indicate that BS50 retains the ability to express antimicrobial compounds (e.g., bacillibactin, bacilysin, fengycin, or surfactin.) and digestive enzymes (e.g., amylase, cellulase, lipase, protease, etc.) to varying extents. The BS50 strain is typically manufactured in pure culture and then spray-dried. [0027] The BS50 strain described herein was originally isolated from composted soil from Gallatin County, Montana, USA and has subsequently been produced in a laboratory and industrial fermentation facility (BIO-CAT Microbials, LLC, Shakopee, Minnesota, USA). Whole genome sequencing and subsequent bioinformatic analysis have shown that the BS50 strain has at least 98.5% similarity to other Bacillus subtilis strains found in the food supply. B. subtilis is not considered pathogenic or toxigenic to humans, animals, or plants and, for example, at least five B. subtilis strains have been classified by the U.S. Food and Drug Administration as Generally Recognized As Safe (GRAS), i.e., GRAS notice numbers (GRN) GRN 831, GRN 905, GRN 955, GRN 956, and GRN 969 (See world wide web at cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNot ices, accessed 09 August 2022). [0028] The spray dried spores of the BS50 strain are highly stable when exposed to high temperatures and for extended periods of time at room temperature. For example, FIG. 1 illustrates that > 80% of BS50 spores remain viable after 120 minutes at 80 ^o C. Greater than 85% of BS50 spores remain viable after 30 minutes at 90 ^o C which is nearly 40% greater viability than other B. subtilis spores (FIG.2). Similarly, FIG.3 illustrates that > 95% of the spray dried BS50 spores remain viable when stored at room temperature (25 ^o C with 65% relative humidity) for at least 9 months. Moreover, as shown in FIG.4, the BS50 strain is highly tolerant to a wide variety of pH levels over time. As a result, the BS50 strain is a good candidate for use in consumer products, such as food, dietary supplement, oral and/or nasal spray, topical skin, and cleaning products, capable of withstanding high temperatures, exposure to room temperature for long periods of time, and/or pH changes. Compositions, Food Products, Beverages and Dietary Supplements Comprising BS50 Cells and/or Spores [0029] BS50 cells and/or spores may be included in a variety of food products, beverages, and dietary supplements in order to provide positive health effects or other benefits. In select aspects, the disclosure provides compositions comprising BS50 cells, spores, or a combination thereof capable of surviving exposure to heat and/or long periods of time at room temperature (e.g., at least 24 months). For example, in some aspects the disclosure provides compositions (e.g., food and beverage products, dietary supplements) comprising BS50 cells, spores, extract, and/or heat-treated forms of either in an amount effective to provide a health benefit to a consumer of a food product, beverage or supplement. [0030] In some aspects, compositions may comprise mutants or derivatives of BS50 having the identifying characteristics of BS50. All mutants or derivatives are isolated without the use of genetic engineering. Furthermore, BS50, its mutants, or its derivative cells, spores, or a combination thereof are produced and harvested by humans in a laboratory or industrial setting. [0031] In some aspects, the composition comprising BS50 cells and/or spores is a food product, such as a baked good. Exemplary baked goods include, but are not limited to, muffins, breads, waffles, cakes, biscuits, cookies, pies, tarts, pastries, candy/energy bars, granola, cereal, crackers. In select aspects, the composition includes any baked good that comprises flour, or which is prepared by baking (e.g., by exposure to dry heat). Other baked goods that may serve as a vehicle for the BS50 include pizza, pasta, corn or potato chips, dehydrated fruits or vegetables. In view of BS50’s tolerance for high temperatures, most baked goods can serve as a delivery system for BS50, providing a variety of new probiotic food options unavailable to many probiotics known in the art. [0032] The BS50 may be included in a beverage composition, whether as vegetative cells, spores, or a combination thereof. In some aspects, the beverage is a hot beverage (e.g., tea, coffee), while in others it is a shelf-stable or cold beverage (e.g., carbonated water, juice, soda, tea, coffee, kefir, kombucha). BS50 spores and/or cells may be added to the beverage during processing by a manufacturer, or by an end user (e.g., by a consumer adding a dry mixture comprising BS50 spores and optionally other nutrients to a water or another liquid to prepare a probiotic meal replacement beverage). In other aspects, the beverage product comprises BS50 and one or more of the following additives: natural sweeteners (e.g., cane sugar, corn syrup, sucrose, maltodextrin, agave syrup or powder, stevia and stevia leaf derivatives, monk fruit powder or extract, etc.), artificial sweeteners (e.g., sucralose, acesulfame potassium, aspartame, etc.), soluble fiber (e.g., pectin, inulin, beta-glucans, fructo-oligosaccharides, galacto- oligosaccharides, xylo-oligosaccharides, arabino-xylooligosaccharides, psyllium, wheat dextrin, polydextrose, carboxymethylcellulose, guar gum and guar gum derivatives, oat powder and other oat derivatives, chickpea powder and other chickpea derivatives, pea powder and other pea derivatives, etc.), insoluble fiber (e.g., cellulose, lignin, wheat bran, etc.), flavoring agents, colorants/dyes, stabilizers, preservatives, oils (e.g., fatty acids, soybean oil, safflower oil, corn oil, peanut oil, coconut oil, medium chain triglycerides, etc.), emulsifiers, vitamins, minerals, proteins, peptides, and/or amino acids. In view of BS50’s broad survivability profile across different temperatures and acidic pH levels, it is understood that BS50 cells or spores may be added to the numerous beverages currently sold or prepared for human consumption. [0033] The BS50 strain and its derivatives may be included in a dietary supplement, whether as vegetative cells, spores, extracts, or a combination thereof. The dietary supplement may be a powder, tablet, pill, sachet, capsule, or suspension. Exemplary dietary supplements include products that may be added to foods or drinks, such as protein powders. In some aspects, the dietary supplement comprises BS50 and one or more of the following additives: natural sweeteners (e.g., cane sugar, corn syrup, sucrose, maltodextrin, agave syrup or powder, stevia and stevia leaf derivatives, monk fruit powder or extract, etc.), artificial sweeteners (e.g., sucralose, acesulfame potassium, aspartame, etc.), soluble fiber (e.g., pectin, inulin, beta- glucans, fructo-oligosaccharides, galacto-oligosaccharides, xylo-oligosaccharides, arabino- xylooligosaccharides, psyllium, wheat dextrin, polydextrose, carboxymethylcellulose, guar gum and guar gum derivatives, oat powder and other oat derivatives, chickpea powder and other chickpea derivatives, pea powder and other pea derivatives, etc.), insoluble fiber (e.g., cellulose, lignin, wheat bran, etc.), flavoring agents, colorants/dyes, stabilizers, preservatives, anti-caking agents, vitamins, minerals, proteins, peptides, and/or amino acids. In other aspects, the dietary supplement is a composition, such as a capsule, comprising BS50 that can be taken with or without food or drink. [0034] In some aspects, the BS50 cells and/or spores may comprise between about 0.001% to about 10% by weight of the food product (e.g., a baked good, granola bar), supplement, or beverage. In other exemplary aspects, the BS50 cells and/or spores may comprise between about 0.01% and about 10% by weight of the food product. Heating and processing will affect the amount or concentration of BS50 is a final product. For example, the amount or concentration of BS50 cells and/or spores present in a baked good will depend on both the number of colony-forming units applied to the pre-baked composition and parameters related to the baking step (e.g., time, temperature, moisture levels). In some aspects, the BS50 cells and/or spores may comprise at least about 0.001%, 0.01%, 0.1%, 1%, or 10% by weight of the food product, or a range between about 0.001% to about 0.01%, about 0.01% to about 0.1%, about 1% to about 10%, about 10% to about 20%, or ≥20% by weight of the food product. It is further understood that in still other aspects, the amount of BS50 cells and/or spores may comprise a minimum and/or a maximum percentage amount selected from any of the aforementioned ranges. [0035] In some aspects, the composition may comprise a mixture or batter for preparing a food product that will be baked (e.g., bread, muffins), fried, or otherwise heated, wherein the mixture comprises BS50 cells and/or spores. The composition may be formulated such that a given percentage (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%) of the BS50 cells and/or spores present in a given amount or volume of the starting mixture or batter remain viable in the final baked, fried, or otherwise heated food product. In some aspects, the composition may be formulated such that about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, or ≥90% of the BS50 cells and/or spores present in a given amount or volume of the starting mixture or batter remain viable in the final baked, fried, or otherwise heated food product. It is further understood that in still other aspects, the percentage of viable cells may be a range that includes a minimum and/or a maximum percentage amount selected from any of the aforementioned ranges. [0036] The following are exemplary food products comprising the BS50 strain. This is a non-exhaustive list, and merely includes various classes of foods and beverages that may serve as a delivery vehicle for BS50 cells and/or spores. Baked goods and baking mixes, including all ready-to-eat and ready-to-bake products, flours, and mixes requiring preparation before serving. Beverages, alcoholic, including malt beverages, wines, distilled liquors, and cocktail mix. Beverages and beverage bases, nonalcoholic, including only special or spiced teas, soft drinks, coffee substitutes, and fruit and vegetable flavored gelatin drinks. Breakfast cereals, including ready-to-eat and instant and regular hot cereals. Cheeses, including curd and whey cheeses, cream, natural, grating, processed, spread, dip, and miscellaneous cheeses. Chewing gum, including all forms. Coffee and tea, including regular, decaffeinated, and instant types. Condiments and relishes, including plain seasoning sauces and spreads, olives, pickles, and relishes, but not spices or herbs. Confections and frostings, including candy and flavored frostings, marshmallows, baking chocolate, and brown, lump, rock, maple, powdered, and raw sugars. Dairy product analogs, including nondairy milk, frozen or liquid creamers, toppings, and other nondairy products. Fats and oils, including margarine, dressings for salads, butter, salad oils, shortenings and cooking oils. Fresh fruit juices, including only raw fruits, citrus, melons, and berries, and home prepared “ades” and punches made therefrom. Frozen dairy desserts and mixes, including ice cream, ice milks, sherbets, and other frozen dairy desserts and specialties. Fruit and water ices, including all frozen fruit and water ices. Gelatins, puddings, and fillings, including flavored gelatin desserts, puddings, custards, parfaits, pie fillings, and gelatin base salads. Grain products and pastas, including macaroni and noodle products, rice dishes, and frozen multicourse meals, without meat or vegetables. Hard candy and cough drops, including all hard type candies. Herbs, seeds, spices, seasonings, blends, extracts, and flavorings, including all natural and artificial spices, blends, and flavors. Jams and jellies, commercial, including only commercially processed jams, jellies, fruit butters, preserves, and sweet spreads. Milk, whole and skim, including only whole, lowfat, and skim fluid milks. Milk products, including flavored milks and milk drinks, dry milks, toppings, snack dips, spreads, weight control milk beverages, and other milk origin products. Nuts and nut products, including whole or shelled tree nuts, peanuts, coconut, and nut and peanut spreads. Plant protein products, including the National Academy of Sciences/ National Research Council “reconstituted vegetable protein” category, and meat, poultry, and fish substitutes, analogs, and extender products made from plant proteins. Processed fruits and fruit juices, including all commercially processed fruits, citrus, berries, and mixtures; salads, juices and juice punches, concentrates, dilutions, “ades”, and drink substitutes made therefrom. Processed vegetables and vegetable juices, including all commercially processed vegetables, vegetable dishes, frozen multicourse vegetable meals, and vegetable juices and blends. Snack foods, including chips, pretzels, and other novelty snacks. Soft candy, including candy bars, chocolates, fudge, mints, and other chewy or nougat candies. Soups and soup mixes, including commercially prepared meat, fish, poultry, vegetable, and combination soups and soup mixes. Sugar, white, granulated, including only white granulated sugar. Sugar substitutes, including granulated, liquid, and tablet sugar substitutes. Sweet sauces, toppings, and syrups, including chocolate, berry, fruit, corn syrup, and maple sweet sauces and toppings. [0037] In some aspects, the disclosure provides probiotic compositions (e.g., food products, beverages, or dietary supplements) comprising BS50 cells and/or endospores that remain shelf stable for long periods of time, such as 4 months, 6 months, 12 months, 18 months, 24 months, 30 months, or more than 30 months at, for example, room temperature. For example, spores added to a granola bar during processing may remain viable for extended periods of time while the bar is stored on a store shelf at room temperature. Compositions may be formulated to increase or decrease stability (e.g., by varying moisture levels). In select aspects, the compositions are formulated to retain a particular percentage of viable cells after a given amount of time stored at room temperature (e.g., at least 50%, 60%, 70%, 80%, or 90%). [0038] In some aspects, the food or dietary supplement comprising the BS50 cells and/or spores may be a spray-dried product (e.g., wherein either the entire product or the BS50 cells and/or spores have been subjected to a spray drying process). Spray drying is a method of producing a dry powder from a liquid or slurry by rapidly drying with a hot gas, and is a preferred method of drying many thermally-sensitive materials, such as foods and pharmaceuticals. Spray drying of the BS50 cells and/or spores may be used to further enhance the survivability of the BS50 in the delivery vehicle. For example, a spray drying step during processing may generate a dry mixture for a food product that displays a higher degree of stability at room temperature than a comparable mixture lacking this spray drying step. Various methods of spray drying are known in the art to be suitable for bacteria and may be used or adapted for use with BS50 cells. For example, spray drying protocols may include carbohydrates, such as polysaccharides or polyols, that enhance preservation by preventing crystallization during the drying step. Similarly, methods known in the art allow for spray drying of bacteria in the presence of inactive agents, such as plasticizers and glidants, so as to produce a particle that provides controlled release after ingestion. It is contemplated that the BS50 cells and/or spores disclosed herein may be spray dried by any methods known in the art suitable for bacteria, particularly methods suitable for B. subtilis. [0039] In other aspects, the BS50 cells, spores, and/or supernatants may be lyophilized. Lyophilization or freeze drying is a method of drying by first freezing a liquid or slurry then removing water from the frozen product. Water removal takes place under a vacuum so solid water leaves the product as a vapor. Because lyophilization does not require heat, this method of drying can be useful to preserve, for example, heat-sensitive vitamins or metabolites produced by the BS50 strain effectively concentrating the beneficial products of BS50 beyond anything found in nature. [0040] In other aspects, the BS50 is heat treated, filtered to remove viable cells, or both. Heating and/or filtering are methods of removing viable cells or spores from the BS50 preparation by using high heat (e.g., greater than 100 ^o C) and/or sterilizing filtration (e.g., 0.2- micron filter) to preserve the beneficial products produced by BS50 without any remaining live component. These cell free preparations are useful for administration to humans and/or animals whereby the beneficial products of the B. subtilis strain BS50 are desired but viable cells are not. [0041] The amount of BS50 cells and/or spores added to a food product, beverage, or dietary supplement may be varied to ensure that a desired number of viable cells remain in the product administered to an end user. This amount may be selected to ensure that the amount present is sufficient to provide a given benefit to the user, such as a reduction in gastrointestinal symptoms. This amount may be selected to ensure that the amount present is sufficient to provide a given benefit to the user, such as an improvement in immune health. The amount may also be varied based upon an expected administration regimen (e.g., a dietary supplement comprising BS50 may be marketed for daily use). Daily use may include a once-daily, twice- daily, or several times daily. In alternative aspects, bidiurnal, once-weekly, twice-weekly and other weekly or longer regimens are possible. Specific regimens and amounts (or concentrations) of the BS50 administered are dictated by the particular application and the parameters needed to achieve an effective amount for a health benefit or other positive effect. [0042] The concentration of BS50 in a given food product, beverage, or dietary supplement may also be varied, for example, to provide an amount effective to achieve a given health benefit. In some aspects, the concentration of BS50 in the food product, beverage, or dietary supplement is about 10 ² to 10 ¹⁰ CFUs of BS50 per gram. In other aspects, the concentration may comprise 10 ⁴ to 10 ⁸ CFU/g, or 10 ⁶ to 10 ⁷ CFU/g. In other aspects, the concentration may comprise 1 x 10 ⁹ to 1 x 10 ¹⁰ CFU/g or 1 x 10 ⁹ to 1 x 10 ¹¹ CFU/g. In some aspects, the amount or concentration of BS50 may be determined on a per unit basis (e.g., up to 1×10 ⁹ CFU or 5 x 10 ⁹ CFU per serving). In some aspects, the concentration may be measured on a per food product, beverage product, or dietary supplement basis. In other aspects, the amount of BS50 is determined on a daily or weekly basis, such as 1-10 x 10 ⁹ CFUs/day, or 1-2 x 10 ¹⁰ CFUs/week. [0043] When administered as a dietary supplement, the daily intake level for BS50 may be approximately 1 x 10 ⁹ to 1 x 10 ¹⁰ CFUs of BS50/day, though the amount may vary within that range based upon the particular application and intended effect (e.g., 5 x 10 ⁹ CFU/day). Dietary supplements may be formulated to include an amount of BS50 CFUs sufficient to achieve any of these daily intake amounts when administered per instructions or expected use by a consumer (e.g., a twice-daily supplement may comprise 5 x 10 ⁹ CFUs per serving in order to reach a recommended daily intake of 1 x 10 ¹⁰ ). Amounts will vary depending on whether the supplement is once-daily, twice-daily, etc. and the total daily intake recommended for the individual or animal. [0044] When administered as a food product, in some aspects the product may be formulated to satisfy a recommended daily intake of up to 2 x 10 ⁹ CFUs. For example, a food or beverage product expected to be consumed at a rate of two servings per day may be formulated to comprise up to 1 x 10 ⁹ CFUs per serving. Alternatively, if a food or beverage is typically consumed by weight (or volume) and not in discrete servings, the formulation of a food product may be designed to provide a suitable concentration of BS50 per gram or unit of volume. For example, if a consumer typically ingests 10 grams of a particular food product per day, the product may be formulated to include approximately to 2 x 10 ⁸ CFUs/gram. Other formulations may take into account a higher or lower expected number of servings or amount consumed per day, or based on the particular application. for example, when administered as a protein powder or sports nutrition drink, in some aspects the BS50 may be included at approximately 1 x 10 ⁹ or 2 x 10 ⁹ CFUs per gram. [0045] In some exemplary aspects, a food product, beverage, dietary supplement or other vehicle for administering BS50 to a human or animal according to any of the aspects described herein may comprise at least one bacterial cell or spore having genomic DNA that is at least 95%, 96%, 97%, 98%, or 99% identical to the genomic DNA of the Bacillus subtilis BS50 which has been deposited under ATCC Accession Number PTA-127287. In some exemplary aspects, the BS50 may be in the form of a vegetative cell, a spore, a heat-killed version of either, or a heat-killed version of both. In some exemplary aspects, the bacterial cell, spore, or heat-killed BS50possesses one or more of the various functional characteristics described herein as a characteristic of BS50 (e.g., the capability to withstand high temperatures, exposure to room temperature for long periods of time, and/or pH changes). It is understood that in some aspects, these bacterial cells, spores, or heat-killed cells or spores may display any of the survivability or stability characteristics of BS50 described herein. These bacterial cells spores, or heat-killed cells or spores may be added to a food product, beverage, supplement, pet food or other vehicle for providing BS50 to a human or pet in any of the amounts of concentrations described herein for BS50, or in other such amounts or concentrations as desired for a given application. [0046] In other aspects, the disclosure provides a composition comprising the isolated BS50 strain, or a cell extract, supernatant, spores, or cell material derived from the isolated strain. [0047] In other aspects, any of the compositions described herein may include suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. In other aspects, any of the compositions described herein may include magnesium stearate, titanium dioxide, stearic acid, cellulose, silicon dioxide, maize (e.g., waxy maize) maltodextrin, microcrystalline cellulose, calcium carbonate, corn starch, maize maltodextrin, tapioca maltodextrin, tapioca dextrin, agenamalt non gmo maltodextrin, calcium chloride, flour salt, potassium sorbate, pretzel salt, sodium benzoate, sodium borate, sodium sulfate (food grade), rice bran extract, and/or potato maltodextrin. [0048] In other aspects, any of the compositions may include additives such as anti-caking agents, anti-oxidation agents, bulking agents, and/or protectants. Examples of additives include polysaccharides (e.g., starches, maltodextrins, methylcelluloses, gums, chitosan and/or inulins), protein sources (e.g., skim-milk powder and/or sweet-whey powder), peptides, sugars (e.g., lactose, trehalose, sucrose and/or dextrose), lipids (e.g., lecithin, vegetable oils and/or mineral oils), salts (e.g., sodium chloride, sodium carbonate, calcium carbonate, chalk, limestone, magnesium carbonate, sodium phosphate, calcium phosphate, magnesium phosphate and/or sodium citrate), and/or silicates (e.g., clays, in particular beolite clay, amorphous silica, fumed/precipitated silicas, zeolites, Fuller’s earth, baylith, clintpolite, montmorillonite, diatomaceous earth, talc, bentonites, and/or silicate salts like aluminum, magnesium and/or calcium silicate). [0049] In other aspects, compositions comprising B. subtilis strain BS50 may be formulated for nasal or topical administration. For example, methods of formulating compositions for nasal administration are disclosed in U.S. Pub. No. 2022/0047627, incorporated herein by reference in its entirety. Methods of Preparing Food Products, Beverages, and Supplements Comprising BS50 Cells and/or Spores [0050] BS50 cells, spores, or heat-killed cells or spores may be added to a variety of food products, beverages, and dietary supplements. In view of BS50’s increased survivability under high heat (e.g., 80ºC), extended periods of time at room temperature, and broad pH conditions, it is envisioned that BS50 cells and/or spores may be applied to most food products, beverages and dietary supplements in their current form, or with minor modifications. For example, BS50 spores may remain viable for at least 24 months at room temperature, (e.g., without refrigeration), making BS50 spores particularly well-suited for products with a long shelf life. [0051] Processing conditions may need to be varied based on the type of food product (e.g., the amount of BS50 cells, spores, or heat-killed cells or spores added to a pre-processed or pre- baked composition may need to be increased in order to ensure sufficient colony-forming units in the end product). Other parameters that may be adjusted include moisture levels, temperature, and pH conditions. For example, if a composition comprising BS50 spores is to be baked at a higher temperature or for a longer time, survivability may be enhanced by increasing the moisture level of the pre-baked composition. Each of the aforementioned parameters may be varied in order to suit a desired application of the methods and compositions disclosed herein. [0052] In certain aspects, the composition is prepared by at least one step involving the application of a high temperature for a short or sustained period of time. For example, the composition may be baked, boiled, or fried. In some aspects, BS50 spores, cells, or a mixture thereof are included in the composition prior to the application of a high temperature. For example, the BS50 cells may be dispersed in a dry mixture, a batter, or a liquid component that is then baked or mixed with additional components prior to baking. [0053] In some aspects, the composition is heated by baking to at least 300, 325, 350, 375, 400, or 425°F for at least 10, 15, 20, 25, or 30 minutes. In select aspects, the composition is a muffin, pancake, bread, cake, biscuit, pancake, or waffle mix comprising BS50 spores or heat killed spores. In some aspects, the BS50 cells and/or spores are pre-mixed into the mixture prior to purchase, while in others the BS50 cells and/or spores may be provided as a separate component in a kit, to be mixed into the composition prior to heating by an end user. [0054] In some aspects, the composition is a composition, such as a pancake comprising BS50 cells, spores, or heat-killed cells or spores, is cooked on a frying pan or griddle. In select aspects, the composition is cooked by heating to 375°F (190.6°C) for at least 2-3 minutes per side. In select aspects, the composition is formulated to retain at least 50% viability of the BS50 cells and/or spores when the mixture is heated to 375°F (190.6°C) for at least 2-3 minutes, twice (e.g., by cooking on each side). [0055] In some aspects, the composition is heated by boiling or steeping BS50 cells, spores, or heat-killed cells or spores in a hot solvent such as water (e.g., a tea bag comprising ground tea leaves, BS50 spores, and optionally other ingredients). In still further aspects, the composition is prepared by mixing a dry component with hot water (e.g., oatmeal comprising BS50 spores). Compositions, Foods, Beverages and Dietary Supplements Comprising BS50 Cells and/or Spores and One or More Additional Bacteria [0056] In some aspects, a composition, food product, beverage, or dietary supplement composition according to the disclosure may comprise BS50 cells, spores, or heat-killed cells or spores according to any of the aspects disclosed herein, in addition to at least one other probiotic. In some aspects, the at least one other probiotic is a probiotic bacterium (e.g., a Lactobacillus species such as L. acidophilus). In other aspects, the bacterium is an Akkermansia, Anaerobutyricum, Bifidobacterium, Clostridium, Enterococcus, Faecalibacterium, Lacticaseibacillus, Lactiplantibacillus, Lactobacillus, Ligilactobacillus, Limosilactobacillus, Propionibacterium, Saccharomyces, or Streptococcus bacterial or fungal strain. In some aspects, the at least other probiotic is a second strain from the genus Bacillus. In some aspects, at least two probiotic strains are present. However, additional compositions featuring multiple probiotics are also contemplated. For example, combination products may comprise refrigerated or non-refrigerated dairy (e.g., yogurt, milk, cheese), and non-dairy products (e.g., a soda, energy drink, or sports drink), fermented products, etc. [0057] The one or more additional probiotics may be present in a composition, food product, beverage, or dietary supplement composition in particular combinations or ratios that provide improved health benefits or other beneficial effects resulting from administration to a human or animal. For example, two strains that each promote gastrointestinal health or a reduction in negative gastrointestinal symptoms, and/or promote immune health, may be combined in a single composition in a ratio that provides a greater benefit that administration of the same amount of each probiotic separately and/or at different times. As indicated above, BS50 is compatible with several other probiotics via streak plate assays and thus may display synergistic effects when paired with these or other members of the Lactobacillus or Bifidobacterium genera, or other probiotics. The amounts, ratios and combinations of probiotics may be varied to achieve different outcomes or efficacy levels. [0058] When BS50 is combined with at least one other probiotic, for example, in a food product, beverage, or dietary supplement, the parameters of the composition may be adjusted to provide an environment conducive to survival of both the BS50 cells and/or spores, and the one or more additional probiotics. For example, compositions featuring a Lactobacillus or Bifidobacterium may be prepared at a lower temperature suitable for these probiotics. While the BS50 strain is particularly well-suited at surviving high temperatures, compositions according to the present disclosure may be prepared at any suitable temperature (e.g., without a heating step), depending on the intended use for the composition and its components. Pet Food Products, Beverages, and Supplements Comprising BS50 Cells and/or Spores [0059] Compositions comprising BS50 formulated for animal consumption are also provided. While the present disclosure has thus far described compositions suitable for a human, there exists an analogous need in the art for new probiotics for animals (e.g., pets or livestock). In particular, there is a need for probiotic compositions that remain viable after long periods of time in storage (e.g., dry pet food). [0060] In some aspects, the composition comprises a wet pet food comprising BS50 cells, spores, or heat-killed cells or spores. In other aspects, the composition comprises a dry pet food comprising BS50 spores. In particular aspects, the composition may be a cat or dog food product, such as a bone. The pet food composition may be coated with the BS50 cells and/or spores, e.g., as an outer layer applied to dry pet food after the individual pieces have been formed, or mixed into the pet food prior to shaping. In other aspects, the composition is a liquid or dietary supplement comprising BS50 cells and/or spores (e.g., which is added to food or water in a dog bowl). In any of the above-identified aspects, the composition may comprise one or more of the following: protein, an amino acid, a plasticizer, a vitamin, and any other components known to be useful for promoting pet health and/or improving flavor. A pet food product, beverage, supplement or other vehicle for providing BS50 to a pet may be formulated to include BS50 cells and/or spores in any amounts or ranges described herein (e.g., any of the amounts and/or ranges described above in the context of food products). Methods of Using Compositions Comprising BS50 Cells and/or Spores [0061] Methods of administering compositions comprising BS50 cells, spores, or heat- killed cells or spores to individuals are also provided. For example, the disclosure provides methods of treating or reducing gastrointestinal symptoms in a human subject. In select aspects, the gastrointestinal symptoms (GI) comprise abdominal bloating, flatulence, burping, stomach rumbling, diarrhea, constipation, loose stool, or firm stool. In other aspects, the disclosure provides methods of promoting immune health in a human subject. In select aspects, immune health is determined by measuring blood levels of the anti-inflammatory cytokine IL-10. IL- 10 is a robust anti-inflammatory and immunosuppressive cytokine protein produced and secreted by many different types of immune cells, and in particular, monocytes, macrophages, regulatory T cells, and T helper type 2 cells. IL-10 plays a role in dampening inflammatory responses, e.g., by inhibiting the release of pro-inflammatory cytokines (Ref: 2008 Couper). In other aspects, immune health is determined by measuring levels of pathogenic bacteria in stool samples. [0062] In some aspects, the disclosure provides for methods of improving GI tolerance, improving GI health, improving GI comfort, improving digestive health, supporting GI tolerance, supporting GI health, supporting GI comfort, supporting digestive health, enhancing GI tolerance, enhancing GI health, enhancing GI comfort, enhancing digestive health, optimizing GI tolerance, optimizing GI health, optimizing GI comfort, optimizing digestive health, promoting GI tolerance, promoting GI health, promoting GI comfort, and/or promoting digestive health by administering any of the compositions comprising BS50 cells and/or spores to individuals described herein. [0063] In other aspects, the disclosure provides for methods of reducing GI symptoms, reducing digestive symptoms, reducing GI discomfort, reducing abdominal discomfort, reducing burping, reducing abdominal bloating, reducing flatulence, alleviating GI symptoms, alleviating digestive symptoms, alleviating GI discomfort, alleviating abdominal discomfort, alleviating burping, alleviating abdominal bloating, alleviating flatulence, helping with occasional gas and bloating, helping with occasional flatulence, and/or helping with occasional burping by administering any of the compositions comprising BS50 cells and/or spores to individuals described herein. In some aspects, “reducing” means reducing the severity or frequency of the condition (e.g., GI symptoms). [0064] In other aspects, the disclosure provides for methods of preventing GI symptoms, preventing digestive symptoms, preventing GI discomfort, preventing abdominal discomfort, preventing burping, preventing abdominal bloating, preventing flatulence, treating GI symptoms, treating digestive symptoms, treating GI discomfort, treating abdominal discomfort, treating burping, treating abdominal bloating, and/or treating flatulence by administering any of the compositions comprising BS50 cells and/or spores to individuals described herein. [0065] In any of the preceding aspects, the term “GI” can be used interchangeably with gut. [0066] In other aspects, the disclosure provides for methods of supporting immune health, supporting immunity, improving immune health, improving immunity, promoting immune health, and/or promoting immunity by administering any of the compositions comprising BS50 cells and/or spores to individuals described herein. [0067] In other aspects, the disclosure provides for methods of reducing inflammation, alleviating inflammation, helping with inflammation, preventing inflammation, and/or treating inflammation by administering any of the compositions comprising BS50 cells and/or spores to individuals described herein. In some aspects, “reducing” means reducing the severity or frequency of the condition (e.g., GI symptoms). [0068] In select aspects, the methods comprise administering a composition (e.g., a food product, dietary supplement, or other vehicle) comprising at least 100, 150, 200, 250, 300, 350, or 400 mg of BS50 spores, to a patient on a daily basis. In some aspects, the BS50 may be administered once-daily, twice-daily (or more frequently). In other aspects it may be once- weekly, twice-weekly, etc. In select aspects, the method comprises administering the composition at least once daily for 1, 2, 3, or 4 or more consecutive weeks, at least 6 months, at least 12 months, or other regimens that may be suitable to provide a desired effect or health benefit. The composition may be administered in any suitable format or vehicle (e.g., as a capsule, tablet, suspension, etc.). In some aspects, the BS50 may be administered to a human once per day as a capsule, tablet, suspension or other dosage form comprising 2 x 10 ⁹ CFU of BS50. Other amounts and formulations may be developed to suit the particular dosage regimen and amount necessary for a given effect. For example, if administered twice-daily, each dosage form may be formulated to comprise 1 x 10 ⁹ CFU of BS50. Liquid dosage forms may be formulated to provide similar amounts (e.g., 2 x 10 ⁹ CFU of BS50) when administered. In some cases, more or less BS50 may need to be administered (e.g. if a percentage of the BS50 is expected to become non-viable during storage, a surplus amount may be included in the dosage form, e.g., capsule). In some aspects, it may be useful to administer higher or lower amounts of BS50 such as any amount between 1-10 x 10 ⁹ per day (e.g., 1 x 10 ⁹ per day, 2 x 10 ⁹ per day, 3 x 10 ⁹ per day, 4 x 10 ⁹ per day, 5 x 10 ⁹ per day, or 1 x 10 ¹⁰ per day). [0069] In other aspects, BS50 may be administered in an aerosol, for example by way of a nasal spray, for instance for administration to the respiratory tract. In other aspects, BS50 may be administered topically, for example by way of a lotion, cream, for instance for administration to the skin. [0070] The BS50 cells, spores, or heat-killed cells or spores composition may be administered to achieve some or all of these effects and may be any of the other food product, beverage, or dietary supplement compositions disclosed herein, provided in an amount and frequency sufficient to achieve the desired effect. [0071] Similar methods may be employed to improve the health of animals, including house pets (e.g., cats, dogs) as well as farm animals (e.g., livestock). BS50 cells, spores, or heat-killed cells or spores may be administered to an animal according to a regimen similar to that used for humans, as discussed above. Alternatively, BS50 cells or spores may be added to an animal’s food on a repeating or as-needed basis. In some aspects, the BS50 may be present in an amount sufficient to provide reduce gastrointestinal symptoms in the animal when administered according to a given regimen. Thus, the present disclosure provides methods of improving the health of an animal by administering an effective amount of BS50 cells and/or spores. Compositions for Inhibiting Microbial Pathogens [0072] Compositions according to the present disclosure may be used to inhibit the growth of pathogenic microbes (e.g., harmful bacteria). In particular, compositions comprising BS50 may be useful to inhibit the growth of Escherichia species (e.g., E. coli), Streptococcus species, Staphylococcus species (e.g., S. aureus, and methicillin-resistant S. aureus “MRSA” strains), Bordetella species, Listeria species (e.g., L. monocytogenes) and Salmonella species (e.g., S. heidelberg). [0073] Antimicrobial compositions comprising BS50 have been tested using cross streak assays against multiple pathogenic bacteria, as described in Example 6. The results show that BS50 displays the ability to inhibit pathogenic members of at least several bacterial genera. These results suggest an additional basis for BS50’s its probiotic effects. As such, compositions comprising BS50, as described herein, may be prepared and used as an antimicrobial treatment. For example, such compositions may be administered to an animal or human, or applied to a surface or area in order to inhibit the growth of a pathogenic bacteria. Antimicrobial compositions for administration to a human or animal may be delivered as part of a supplement, food product, beverage. In some aspects, it may be delivered via a tablet, capsule, spray (e.g., nasal spray) or suspension as described herein. Antimicrobial compositions suitable for application to a surface or area may comprise a liquid, dry mixture, powder or any other vehicle suitable for administering bacterial cells or spores. [0074] In some aspects, inhibitory compositions may comprise a combination of BS50 with one or more other probiotics or other microbes known to display antimicrobial effects. For example, a combination may include BS50 and a second non-pathogenic bacteria known to inhibit one or more pathogenic microbes (e.g., MRSA). The combinations may be formulated and/or selected to provide an additive or synergistic antimicrobial effects against one or more pathogenic bacteria. In some aspects, the pathogenic bacteria is a species selected from one of the following genera: Staphylococcus (e.g., S. aureus, MRSA S. aureus), Listeria (e.g., L. monocytogenes), Salmonella (e.g., S. heidelberg), Streptococcus (e.g., S. agalactiae) Escherichia (e.g., E. coli), or Bordetella (e.g., B. bronchiseptica). Deposit of Biological Material [0075] The Bacillus subtilis strain identified as BS50 was deposited under the terms of the Budapest Treaty on March 29, 2022 with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Virginia 20110-2209, U.S.A., under accession number PTA- PTA-127287. [0076] The following non-limiting examples are provided to further illustrate the embodiments disclosed herein. EXAMPLES Example #1 – BS50 survival during high heat conditions [0077] To determine BS50 spore tolerance to high heat, spray dried BS50 spores were suspended in Butterfield’s Buffer and mixed with a high shear mixing (i.e., kitchen blender). Following mixing, the suspended spores were serially diluted via 10-fold dilution such that the last dilution would deliver approximately 100 colony forming units (CFU) when 100uL was spread plated evenly on the surface of tryptic soy agar (TSA). The final dilution was split into 1mL aliquots in 1.5mL microcentrifuge tubes. Tubes were heated to 70, 80, 90, and 100°C and held at that temperature in a dry bath for up to three hours. At each time point (5, 10, 15, 20, 30, 45, 60, 90, 120, 150, and 180 minutes), a tube was removed and spread plated on triplicate TSA plates. Plates were inverted and incubated at 35°C overnight (18-24 hours). [0078] After incubation, colonies were counted and recorded using InterScience Scan 500 colony counting software. The number of colonies per plate were multiplied by the total dilution factor to determine CFU/mL Percent survival was determined by comparing CFU/mL at each time point to the CFU/mL at time zero at room temperature (20-23°C). [0079] The results of this assay are shown in FIG.1. BS50 was stable for at least 2 hours at 70 and 80°C with greater than 80% viability. Remarkably, BS50 was greater than 85% viable after 30 minutes at 90°C. This durability at 90°C is notable even for spore formers as shown by the comparison in FIG. 2 of BS50 spores and other Bacillus subtilis spores. BS50 spores have a heat tolerance profile that makes them suitable for many higher heat food and beverage processes and compositions. Example #2 – BS50 production of digestive enzymes [0080] Bacillus strains are known to produce a variety of extracellular hydrolytic enzymes. In this assay, agar-based screens were used to determine the relative amount of enzyme activity (amylase, protease, lipase, and cellulase) produced by 36 different Bacillus subtilis strains including BS50. Enzyme specific substrates were incorporated into agar-based media. Media was sterilized, cooled, and poured into sterile empty Petri plates. Once solidified, the surface of the agar media was inoculated with 10uL of an enzyme control or a Bacillus subtilis strain colony suspension equivalent to a 0.5 McFarland standard. After appropriate incubation (typically 35 ^o C for 24 hours) and processing (e.g., staining, counter staining), measurements of clearing zones indicating enzyme activity were taken to the nearest mm with calipers. Results from the test organism were expressed as no (0), low (1), medium (2), or high (3) amounts of extracellular enzyme activity, relative to enzyme control. [0081] Bacillus subtilis strains generally have the ability to produce amylase, protease, lipase, and cellulase but not all strains produce all enzymes and the level of activity also differs between strains. BS50 has greater amylase (2.0 vs 1.8), protease (3.0 vs 1.9), lipase (2.0 vs 1.3), and cellulase (3.0 vs 2.4) activity than the average activity of 35 other Bacillus subtilis strains. Notably, BS50 has as much protease activity as the enzyme control. Example #3 – BS50 in baked goods [0082] A series of baking experiments were conducted to evaluate how well BS50 survives the baking process. BS50 survivability was assessed by comparing the number of BS50 spores in baked muffins and cookies to the amount of BS50 added to the respective batter. Store- bought boxed muffin mix (ingredients including enriched bleached flour (wheat flour, malted barley flour, niacin, reduced iron, thiamin mononitrate, riboflavin, folic acid), sugar, food starch-modified, natural flavor, salt, dextrose, arabic gum, soybean oil, leavening (baking soda, sodium aluminum phosphate), tapioca starch, xanthan gum, citric acid) was prepared per the manufacturer directions with the exception of the addition of BS50. BS50 powder was added to the dry muffin mix to achieve 2 x 10 ⁹ CFU per muffin. The wet ingredients consisting of 2/3 cup water, 1/2 cup vegetable oil, and 2 eggs were then hand mixed then added to the dry ingredients containing BS50 per manufacturer directions. Finally, the box mix pre-packaged blueberry fruit was incorporated into the batter. The mixed batter was weighed into foil baking cups to ensure each muffin was 40 ± 1.0 grams before baking. Remaining batter was used to enumerate and confirm, in triplicate, the amount of BS50 in the batter prior to baking. [0083] The muffins were baked per the manufacturer’s recommended guidelines for baking time and temperature for baking 12 standard size muffins (18-22 minutes at 400°F (204.4°C)). After baking for 18 minutes, the muffins were allowed to cool for at least one hour. Post-baking weight for each muffin were recorded before each muffin was homogenized for enumeration of BS50. [0084] After baking, each muffin was added to a blending jar containing 180 mL Butterfield’s buffer and then homogenized by high-speed blending for 2 minutes with a standard kitchen and bar blender. The homogenized muffins samples were serially diluted (10- fold dilutions), plated on the surface of TSA plates using a spiral plater (EasySprial Pro, InterScience), and incubated at 35°C overnight. After incubation, colonies were counted and recorded using InterScience Scan 500 colony counting software. The number of colonies per plate were multiplied by the total dilution factor to determine CFU/g. Percent survival was determined by comparing CFU/g post baking to target. Data are presented as the average of at least two trials. [0085] Based on the target dose of 2 billion CFU per muffin, 100% of BS50 spores survived the batter mixing process exemplified by the enumeration of unbaked wet batter.63% of the spores survived the baking process and remained viable in the fully baked muffins. [0086] Store-bought dry chocolate chip cookie mix (ingredients including Enriched Flour Bleached (wheat flour, niacin, iron, thiamin mononitrate, riboflavin, folic acid), Chocolate Chips (sugar, chocolate liquor, cocoa butter, soy lecithin, natural flavor), Brown Sugar, Sugar, Palm Oil, Leavening (baking soda, sodium aluminum phosphate), Salt, and Nonfat Milk) was prepared per the manufacturer directions with the exception of the addition of BS50. BS50 was incorporated into the dry ingredients to achieve 2 x 10 ⁹ CFU per cookie. Other ingredients including 1 egg and 1 stick (1/2 cup) of softened butter were then added to the dry mix. Cookie dough was weighed to achieve 23 ± 0.5 g per cookie, dispensed onto baking sheet trays and baked at 350°F (176.6°C) for 12-14 minutes until golden brown. The baked cookies were allowed to cool for 15 minutes before determining post-baking weight. [0087] After baking, each cookie was added to a blending jar containing 180 mL Butterfield’s buffer and then homogenized by high-speed blending for 2 minutes with a standard kitchen and bar blender. The homogenized cookie samples were serially diluted (10- fold dilutions), plated on the surface of TSA plates using a spiral plater (EasySprial Pro, InterScience), and incubated at 35°C overnight. After incubation, colonies were counted and recorded using InterScience Scan 500 colony counting software. The number of colonies per plate were multiplied by the total dilution factor to determine CFU/g. Percent survival was determined by comparing CFU/g post baking to target. Data is presented as the average of at least two trials. [0088] Based on the target dose of 2 billion CFU per cookie, 100% of the spores survived the batter mixing process exemplified by the enumeration of unbaked wet dough.76% of the spores survived the baking process and remained viable in the fully baked cookies. Both baking experiments support the use of BS50 in foods that are cooked or baked at high temperatures. Example #4 – Hot Beverage [0089] To evaluate BS50 stability in hot beverage matrices, BS50 spore preparation was added to store bought pekoe cut black tea teabags to achieve 2 billion CFU per teabag. Per the manufacturer instructions, each teabag was steeped in 8 oz (227 g) of water for 3 minutes. The teabags were steeped in hot water held at 90 °C, 95 °C or 100 °C. After steeping for 3 minutes, the resulting hot tea was serially diluted (10-fold dilutions), plated on the surface of TSA plates using a spiral plater (EasySprial Pro, InterScience), and incubated at 35°C overnight. After incubation, colonies were counted and recorded using InterScience Scan 500 colony counting software. The number of colonies per plate were multiplied by the total dilution factor to determine CFU/mL. Percent survival was determined by comparing CFU/mL in the tea to the target dose. Data is presented as the average of at least two trials. [0090] Based on the target dose of 2 billion CFU per teabag, the final tea was expected to contain 8.8 million CFU/mL of BS50 spores. Based on 8.8 million CFU/mL, 100% of the BS50 spores survived and remained viable after steeping for 3 minutes at 90 °C as shown in FIG.5. While increased steeping temperatures decreased the BS50 spore survival, at least 50% of the spores survived steeping temperatures up to 100 °C. This further supports the use of BS50 in food and beverage applications where elevated temperature are used in processing. [0091] A similar experiment was conducted by adding BS50 to ground coffee and brewing the resulting grounds. BS50 was mixed into classic roast coffee grounds such that a 6 oz (177 mL) serving of coffee would contain 2 billion CFU of BS50. The coffee was brewed using a standard store-bought electric drip coffee maker. The resulting coffee was serially diluted (10- fold dilutions), plated on the surface of TSA plates using a spiral plater (EasySprial Pro, InterScience), and incubated at 35°C overnight. After incubation, colonies were counted and recorded using InterScience Scan 500 colony counting software. The number of colonies per plate were multiplied by the total dilution factor to determine CFU/g. Percent survival was determined by comparing CFU/mL in the coffee to the target dose. Data is presented as the average of at least two trials. [0092] More than 95% of the BS50 spores passed through the coffee grounds and coffee filter into the brewed coffee. Less than 5% of the BS50 spores remained in the used coffee grounds and coffee filter. Based on a 2 billion CFU per 6 oz (177 mL) cup of coffee dose, the final coffee was expected to contain 11 million CFU/mL of BS50. The brewed coffee contained 14 million CFU/mL of BS50 representing 100% survival of BS50. Example #5 – Cross Streak Compatibility Test [0093] Compatibility between BS50 with other known non-spore forming probiotic species was investigated via cross streak assay. MRS agar supplemented with 0.05% L-cysteine was inoculated with a loopful of BS50 streaked down the center of the plate. The plate was incubated aerobically at 35 ± 2°C for 18-24 hrs to allow for robust BS50 growth. After initial incubation, various LAB (lactic acid bacteria) probiotic strains including Bifidobacterium spp. (Bifidobacterium animalis, Bifidobacterium adolescentis, and Bifidobacterium bifidum), Lacticaseibacillus rhamnosus (formerly Lactobacillus rhamnosus), Lactiplantibacillus plantarum (formerly Lactobacillus plantarum) and Lactobacillus acidophilus were individually streaked onto the surface of the agar perpendicular to the BS50 center streak without touching the center streak. The perpendicular streaks were streaked starting near the BS50 center streak moving towards the edge of the plate. The cross-streak plates were placed into an anaerobic chamber with anaerobic sachets (BD GasPak EZ Container Systems) and incubated at 35 ± 2°C for 48 hours. The plates were inspected for signs of growth inhibition near the streak junction. The degree of inhibition of the LAB strains was measured using calipers to measure the distance (mm) between the center streak and the beginning of growth of the perpendicular. [0094] B. subtilis BS50 was compatible with 5 of the 6 LAB probiotic strains tested as shown by the lack of growth inhibition (i.e., no clearing zones) in FIG.6. BS50 does appear to be somewhat inhibitory towards Bifidobacterium bifidum given the 6.75 mm clearing zone between the BS50 center streak and the growth of the B. bifidum cross streak. Other similar Bacillus strains also appear to inhibit to varying degrees B. bifidum (BCM data not shown). The BS50 compatibility with multiple LAB probiotics provides options for compositions comprising one or more additional LAB probiotics. Example #6 – Cross Streak Assays to Evaluate BS50’s Potential to Inhibit the Growth of Pathogenic Bacteria [0095] To conduct this assay, isolated colonies of BS50 were suspended in sterile water to a 0.5 McFarland standard. Using a 10 μL calibrated loop, BS50 inoculum streaked in a single line down the middle of a TSA plates and plates were incubated at 35°C for 18-24 hours to allow the BS50 to grow on the surface of the plate. [0096] Each test organism (Escherichia coli, Streptococcus agalactiae, Pseudomonas aeruginosa, Staphylococcus aureus, Salmonella enterica Salmonella typhimurium, Salmonella heidelberg, Pasteurella multocida, Bordetella bronchiseptica, and Listeria monocytogenes) was suspended in sterile water to a 0.5 McFarland equivalent. Using a 10 μL calibrated loop, each inoculum was streaked perpendicular up to, but not touching, the BS50 streak. Each cross- streaked test organism was streaked onto 3 separate BS50 test plates to allow for measurement of inhibition in triplicate. All cross-streaked plates were incubated at 35°C for 24 hours to allow test organisms to grow. [0097] Zones of inhibition were then measured in millimeters from the edge of growth of the center BS50 streak to the beginning of growth of the test organism using calipers. The average value from the triplicate measure was determined. The results of this assay shown in FIG. 7 indicate that BS50 demonstrates antimicrobial effects against members of several pathogenic genera including Escherichia, Streptococcus, Staphylococcus, Bordetella, Listeria, and Salmonella. These results suggest a possible basis for its probiotic effects and its usefulness in health-promoting and decolonization as disclosed herein. Example #7 – BS50 Stability in a Gummy Preparation [0098] Pectin- and gelatin-based gummy preparations are a popular format for dietary supplements. Gummy-based vitamin, calcium and probiotic supplements are commercially available. However, some agents and in particular probiotic agents, are incompatible with gummy preparations and/or manufacturing procedures used to create such preparations. [0099] To determine the compatibility of BS50 in gummy preparations, gelatin-based, unflavored gummies containing 2 billion CFU per gummy of BS50 were prepared and sealed in a clear plastic bottle or Alu pouch. [00100] After manufacture, 4 gummies (approx. 20 grams) were hydrated in 180mL of Butterfield’s buffer and heated to 60 ^o C for 5 minutes to aid in the dissolving process. Following the heating, gummy suspension was blended for 90 seconds using a standard kitchen blender to obtain a homogeneous gummy solution. After mixing, a 10-fold dilution series was completed and the final dilution as plated on triplicate TSA. The TSA plates were incubated inverted at 35 ^o C for 18-24 hours. Resulting colonies per plate were counted and recorded. The number of colonies per plate were multiplied by the total dilution factor to determine CFU/mL. CFU/mL were then translated into CFU/gummy. Percent survival was determined by comparing CFU/gummy to the expected formulation value. [00101] Greater than 80% of the BS50 spores were viable in the manufactured gummy indicating that BS50 is suited for use in gummy applications. Furthermore, BS50 viability is stable in gummies stored at room temperature over time. Example #8 – Clinical Evaluation of the Effects of BS50 Supplementation on Gastrointestinal Symptoms and Immune Health Markers. [00102] B. subtilis probiotics have been demonstrated to modulate several functions and characteristics of the human gastrointestinal tract, including macronutrient digestion, gut motility, inflammation, microbiota composition, short chain fatty acid profile, and pathogen profile. As shown in Example 2 above, BS50 secretes digestive enzymes and candidate gut microbiota-modulating molecules which may help support digestion, support GI health, and support immune health. BS50 also showed robust heat resistance and pH tolerance, which predicts strain survival across the wide pH range of the human gut. To investigate the clinical efficacy of BS50, 76 human subjects were evaluated by a daily gastrointestinal tolerance questionnaire (GITQ) over the course of 6 weeks of daily probiotic or placebo supplementation. The daily, 8-item QITQ scored the presence and severity of each of flatulence, abdominal bloating, burping, abdominal cramping, stomach rumbling, reflux, nausea, and vomiting. Efficacy was based on specifically a 3-item composite score of flatulence, abdominal bloating, and burping. Statistically significant results showed that the proportion of subjects in the BS50 group with an improvement (or lowering) of the 3-item composite GITQ score was greater than that of the placebo group after 6 weeks of daily supplementation (47.4% vs 22.2%, p = 0.024). These clinical trial data shows that BS50 supports GI health by improving GI tolerance and reducing common GI symptoms. These clinical trial data also demonstrate that BS50 supports immune health by maintaining or increasing plasma levels of interleukin-10, an anti- inflammatory cytokine released by immune cells. [00103] The purpose of this randomized, double-blind, placebo-controlled, parallel arm clinical trial was to evaluate the effects of BS50 supplementation, using the B. subtilis strain BS50 described herein, on GI tolerance and common GI symptoms in healthy adult subjects. 76 eligible participants (30-65 years of age at the time of participation) were randomized into groups given either daily 2 x 10 ⁹ CFU/capsule BS50 (n = 38) or placebo (n = 38). Each group was instructed to consume one capsule per day, with their largest meal, for 6 weeks. Efficacy was assessed through daily, subject-reported GITQ responses. Healthy men and women, age 30 to 65 years (inclusive), who had a body mass index (BMI) 18.0-31.99 kg/m ² (inclusive) and a combined weekly total symptom score for flatulence, abdominal bloating, and burping of ≥3 as assessed using the GITQ. They were also required to consume a typical American diet (defined as ≤3 servings/day of fruits and vegetables combined and <3 servings/day of whole grains). Subjects were enrolled such that the overall population consisted of: 1) 40-60% of one gender (male or female), and 2) 40-60% of one body mass index (BMI) category (18.0-24.99 kg/m ² or 25-31.99 kg/m ² ). [00104] At Visit 1 (Day -7), subjects arrived at the clinic in a fasting state (12 ± 2 h). After subjects provided voluntary informed consent, subjects underwent medical history, prior and current medication/supplement use, inclusion and exclusion criteria assessments. Additionally, height, body weight, and vital signs were measured and BMI was calculated. Blood samples were collected for chemistry and hematology analyses. Subjects were dispensed a paper 3-day Diet Record with instructions to record all foods and beverages consumed during 3 days (1 weekend day and 2 weekdays) prior to Visit 2 (Day 0). Subjects were also dispensed a paper GITQ with instructions to rate the severity of daily GI symptoms occurring from the morning of Day -7 through the morning of Day -0, just before their Visit 2. The GITQ contained a series of questions regarding the presence and severity of GI symptoms occurring during the past 24 h. Therefore, subjects reported GI symptoms for Day -7 on Day -6, for Day -6 on Day -5, for Day -5 on Day -4, etc. Individual components included the severity of GI symptoms including flatulence, abdominal distention/bloating, burping, borborygmus/stomach rumbling, abdominal cramping, reflux (heartburn), nausea, and vomiting, and these were ranked on a 4- point scale ranging from none (score 0) to severe (score 3). GITQ is hereby incorporated by reference and has been previously described in a number of well-designed, peer-reviewed, and published clinical trials (See Boler, B. M., et al. (2011). “Digestive Physiological Outcomes Related to Polydextrose and Soluble Maize Fibre Consumption by Healthy Adult Men.” The British Journal of Nutrition. 106(12), 1864–1871 and Holscher, H. D., et al. (2014). “Gastrointestinal Tolerance and Utilization of Agave Inulin by Healthy Adults.” Food & Function. 5(6), 1142–1149, the entire contents of each of which are incorporated herein by reference). Subjects completed a paper GITQ during the 7 days immediately prior to Visit 2 (Day 0) for collection of baseline information. Therefore, subjects were instructed to complete their first GITQ on the morning of Day -6 and the final GITQ on the morning of Day 0, just before their Visit 2. [00105] At Visit 2 (Day 0), subjects arrived at the clinic in a fasting state (12 ± 2 h). Subjects underwent clinic visit procedures (concomitant medication/supplement use, inclusion/exclusion criteria assessment, body weight and vital signs measurements), and adverse event (AE) assessment. The paper 3-day Diet Record and GITQ were collected and reviewed. Blood samples were collected for assessment of markers of inflammation. Subjects were randomly assigned to a study product. Subjects were then dispensed their assigned study product and instructed to consume it once a day (1 capsule/day) with the meal that is typically their largest of the day. Subjects were dispensed the electronic GITQ with instructions to capture events occurring daily leading up to Visit 3 (Day 42). Subjects were instructed to report GI symptoms daily for the 6 weeks of study product consumption using the electronic GITQ whereby the link to the questionnaire was emailed to subjects daily. Subjects were instructed to start filling in their first GITQ ~24 h after the consumption of their first product and before the consumption of the second study product. For example, if study product consumption occurred at 12 pm on Day 0 with lunch, the first GITQ should be completed the afternoon (12 pm or later) of Day 1 before Day 1’s study product consumption to enable subjects to record any events occurring from 12 pm on Day 0 to 12 pm on Day 1. The final GITQ was completed the morning of Day 42, immediately prior to Visit 3. Subjects were also dispensed a paper Study Product Log with instructions to record the date and time of each study product consumption event. Weekly email reminders to consume the study product and complete the questionnaire were sent to subjects to encourage compliance. [00106] At Visit 3 (Day 42), subjects arrived at the clinic fasted (12 ± 2 h) and underwent clinic visit procedures (concomitant medication/supplement use, inclusion/exclusion criteria assessment, body weight and vital signs measurements), and adverse event (AE) assessment. Blood samples were collected for chemistry and hematology analyses as well as for assessment of markers of inflammation. Compliance to study product consumption was assessed by review of the paper Study Product Log and counting of returned unused study product. Fasting interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis factor- alpha (TNF-α) were measured by PBL Assay Science (Piscataway, NJ) with the U-PLEX biomarker group 1 human assay kit by Meso Scale Diagnostics (Catalog number K15067L-1). [00107] The effect of BS50 was defined by the difference between BS50 and placebo products in the proportion of subjects with a decrease (indicating an improvement in symptoms) in the 7-day total 3-item composite intensity score of flatulence, abdominal bloating, and/or burping, where an increase in score (indicating worsening) cannot occur in any symptom. Improvement was defined by if the change from baseline to Day 42 in the total 3- item composite intensity score (flatulence + abdominal bloating + burping) decreased by at least 2 points (i.e. composite score change ≤ -2), requiring that no worsening occurred in any of the three symptoms (i.e. each individual score change >1). Secondary outcome included the difference in blood concentrations of the anti-inflammatory cytokine IL-10. [00108] The proportion of subjects that had an improvement in the 7-day total composite score of flatulence, abdominal bloating, and burping (3-item composite) were compared between groups with the chi-square test. The odds of observing an improvement in symptoms were then modelled with logistic regression and adjusted for sex and BMI group. The proportion of subjects with an improvement in each individual GI symptom (defined as a 1 point decrease) was compared between groups with a chi-square test; if the cell count was < 5, a Fisher’s exact test was used. The 3-item weekly composite score was analyzed with a repeated measures model where the within subject correlation was modeled with an AR(1) covariance structure. The model contained fixed effect terms for product, week, product × week interaction, sex, and BMI group. Contrast/estimate statements were used to estimate the difference (95% confidence interval) between products in the change from baseline to each follow-up time point. Additionally, the within product change from baseline to each follow-up time point was estimated along with a 95% confidence interval. Blood inflammation markers were compared between products with the analysis of covariance (ANCOVA) approach. The change from baseline was used as the outcome and adjusted for baseline, product, sex, and BMI group. Note that the estimated product effect from an ANCOVA model for the change score is equivalent to a model of just Day 42 values. For the blood inflammation markers, model assumptions were violated and the rank transformation was used. As a sensitivity analysis, the Wilcoxon rank sum test and the stratified Wilcoxon test was also used to evaluate differences between products at Day 0, Day 42, and the change from Day 0 to Day 42. [00109] Table A reports the subject characteristics at screening. Based on returned unused study product, the mean compliance was 101.0%. Specifically, the compliance for BS50 was 100.9% ± 5.2%, and the compliance for the placebo was 101.0%. Table B shows the proportion of subjects demonstrating an improvement in the 7-day composite score for 3 items: flatulence, bloating, and burping. Improvement was defined as having a decrease of at least 2 in composite score without any increase in scores for the individual symptoms measured the 7 days prior to Day 42 compared to the 7 days prior to Day 0. A significant difference was detected in the proportion of subjects with an improvement in the 7-day 3-item composite score (47.4% in the BS50 group vs 22.2% in the placebo group), whereby the odds of detecting an improvement were higher (p = 0.024 chi-square; p = 0.026 logistic regression adjusted for sex and BMI group) following BS50 compared to placebo (shown in Table B).

^a Improvement was defined as having a decrease of at least 2 in the composite score without any increase in scores for the individual symptoms measured the 7 days prior to Day 42 as compared to the 7 days prior to Day 0. bDoes not adjust for sex and body mass index groups. This is defined as the primary analysis in the Statistical Analysis Plan. cThe proportion of subjects that had an improvement in the 7-day 3-item total composite score were compared between groups with the chi-square test. dThe odds of observing an improvement in symptoms were modeled with logistic regression and adjusted for sex and body mass index group. n, sample size; OR, odds ratio; CI, confidence interval [00110] The proportion of subjects who had weekly improvements or no improvements for burping, bloating, and flatulence are shown in Tables C, D, and E, respectively. Improvement was defined as showing score decrease of at least 1 and no improvement was defined as no change in score or showing a score increase (indicating worsening of symptom). A statistically significant (p = 0.041) greater proportion of subjects showed improvements in burping following BS50 compared to placebo (44.7% in the BS50 group vs 22.2% in the placebo group, see Table C). There was a trend (p = 0.071) for a greater proportion of subjects with improvement in bloating following BS50 compared to placebo (31.6% in the BS50 group vs 13.9% in the placebo group, see Table D). No statistically significant differences were observed in the proportion of subjects showing improvements in flatulence following BS50 compared to placebo (Table E).

aImprovement was defined as showing flatulence score decrease of at least 1 and no improvement was defined as no change in score or showing a score increase (indicating worsening of symptom) prior to Day 42 as compared to the 7 days prior to Day 0. n, sample size; OR, odds ratio; CI, confidence interval [00111] All data shown describe results from a conservative analysis of all enrollees (i.e., the “intent to treat” population). The per protocol population comprised a reduced number of subjects due to removal of 2 subjects that deviated from one or more aspects of the study protocol (i.e., end of study visit out of window). Baseline, Day 42, and change at Day 42 from baseline for plasma IL-6, IL-8, IL-10, and TNF-α are shown in Table F. Differences in the change from baseline to the end of the study Day 42 in the anti-inflammatory cytokine IL-10 was suggested (p = 0.13 in the intent to treat population; P = 0.047 in the per protocol population), whereby the difference is driven by a decrease in the placebo group and an increase in the BS50 group. There are no other notable differences across the pro-inflammatory cytokines IL-6, IL-8, and TNF-α.

[00112] This is the first randomized, double-blind, placebo-controlled, parallel study on the efficacy of BS50 in relieving the combination of gas, bloating, and burping symptoms in healthy persons. The results demonstrate that daily supplementation of 2x10 ⁹ CFU/day BS50 increased the proportion of subjects showing improvement in the composite score for flatulence, bloating, and burping. BS50 also improved the individual symptoms of burping and bloating at 6 weeks compared to placebo. BS50 supplementation was associated with an increase in circulating levels of the anti-inflammatory cytokine IL-10, compared to placebo, without an increase in three pro-inflammatory cytokines tested. Modulation of IL-10 concentrations and the immune system are candidate mechanisms of action whereby BS50 lessens GI symptoms and supports GI health and digestive health.